Regulation of MYC expression and differential JQ1 sensitivity in cancer cells

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Fowler, Trent ^a   Ghatak, Payel ^a   Price, David H ^b   Conaway, Ronald ^c   Conaway, Joan ^c   Chiang, Cheng Ming ^d   Bradner, James E ^e   Shilatifard, Ali ^c   Roy, Ananda L ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c STOWERS INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE H3; JQ 1; MYC PROTEIN; PEPTIDES AND PROTEINS; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN BRD4; PROTEIN GDOWN1; PROTEIN MED26; RNA POLYMERASE II; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HISTONE METHYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE MYC;

AZEPINES; BLOTTING, WESTERN; BURKITT LYMPHOMA; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDIATOR COMPLEX; NEOPLASMS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA POLYMERASE II; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRIAZOLES; TUMOR CELLS, CULTURED;

EID: 84899862309     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087003     Document Type: Article

References (53)

1. Young RM, Turner BC, Refaeli Y (2008) B-cell receptor signaling in the genesis and maintenance of B-cell lymphoma. Future Oncol 4: 591-594.
2. Refaeli Y, Young RM, Turner BC, Duda J, Field KA, et al. (2008) The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol 6: e152.
3. Shaffer AL, 3rd, Young RM, Staudt LM (2012) Pathogenesis of human B cell lymphomas. Annu Rev Immunol 30: 565-610.
4. Schrader A, Bentink S, Spang R, Lenze D, Hummel M, et al. (2012) High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas. Int J Cancer 131: E348-361.
5. Ahmadiyeh N, Pomerantz MM, Grisanzio C, Herman P, Jia L, et al. (2010) 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A 107: 9742-9746.
6. Selvanayagam P, Blick M, Narni F, van Tuinen P, Ledbetter DH, et al. (1988) Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma. Blood 71: 30-35. (Pubitemid 18050386)
7. Dang CV (2012) MYC on the path to cancer. Cell 149: 22-35.
8. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, et al. (2012) Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151: 56-67.
9. Nie Z, Hu G, Wei G, Cui K, Yamane A, et al. (2012) c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151: 68-79.
10. Fowler T, Sen R, Roy AL (2011) Regulation of primary response genes. Mol Cell 44: 348-360.
11. Muller S, Filippakopoulos P, Knapp S (2011) Bromodomains as therapeutic targets. Expert Rev Mol Med 13: e29.
12. Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K (2003) The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci U S A 100: 8758-8763. (Pubitemid 36899172)
13. Zhou Q, Li T, Price DH (2012) RNA polymerase II elongation control. Annu Rev Biochem 81: 119-143.
14. Guo J, Price DH (2013) RNA Polymerase II Transcription Elongation Control. Chem Rev. 113: 8583-603.
15. Miyoshi S, Ooike S, Iwata K, Hikawa H, Sugaraha K (2009). International Patent No. PCT/JP2008/073864 (WO/2009/084693).
16. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
17. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, et al. (2010) Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
18. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, et al. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468: 1119-1123.
19. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, et al. (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 108: 16669-16674.
20. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R (1979) Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 122: 549-554. (Pubitemid 9089211)
21. Takada K, Ono Y (1989) Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol 63: 445-449. (Pubitemid 19028127)
22. Pulvertaft JV (1964) Cytology of Burkitt's Tumour (African Lymphoma). Lancet 1: 238-240.
23. Clements GB, Klein G, Povey S (1975) Production by EBV infection of an EBNA-positive subline from an EBNA-negative human lymphoma cell line without detectable EBV DNA. Int J Cancer 16: 125-133.
24. Puck TT, Fisher HW (1956) Genetics of Somatic Mammalian Cells: I. Demonstration of the Existence of Mutants with Different Growth Requirements in a Human Cancer Cell Strain (Hela). J Exp Med 104: 427-434.
25. Fowler T, Suh H, Buratowski S, Roy AL (2013) Regulation of primary response genes in B cells. J Biol Chem 288: 14906-14916.
26. Wu SY, Lee AY, Lai HT, Zhang H, Chiang CM (2013) Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell 49: 843-857.
27. Wu SY, Lee AY, Hou SY, Kemper JK, Erdjument-Bromage H, et al. (2006) Brd4 links chromatin targeting to HPV transcriptional silencing. Genes Dev 20: 2383-2396. (Pubitemid 44320387)
28. Cheng B, Li T, Rahl PB, Adamson TE, Loudas NB, et al. (2012) Functional association of Gdown1 with RNA polymerase II poised on human genes. Mol Cell 45: 38-50.
29. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, et al. (2010) AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 37: 429-437.
30. Maguire RT, Robins TS, Thorgeirsson SS, Heilman CA (1983) Expression of cellular myc and mos genes in undifferentiated B cell lymphomas of Burkitt and non-Burkitt types. Proc Natl Acad Sci U S A 80: 1947-1950. (Pubitemid 13079213)
31. Bhatt DM, Pandya-Jones A, Tong AJ, Barozzi I, Lissner MM, et al. (2012) Transcript dynamics of proinflammatory genes revealed by sequence analysis of subcellular RNA fractions. Cell 150: 279-290.
32. Seila AC, Core LJ, Lis JT, Sharp PA (2009) Divergent transcription: a new feature of active promoters. Cell Cycle 8: 2557-2564.
33. Klemsz MJ, Justement LB, Palmer E, Cambier JC (1989) Induction of c-fos and c-myc expression during B cell activation by IL-4 and immunoglobulin binding ligands. J Immunol 143: 1032-1039. (Pubitemid 19203837)
34. Lee BK, Bhinge AA, Battenhouse A, McDaniell RM, Liu Z, et al. (2012) Cell-type specific and combinatorial usage of diverse transcription factors revealed by genome-wide binding studies in multiple human cells. Genome Res 22: 9-24.
35. Gilchrist DA, Dos Santos G, Fargo DC, Xie B, Gao Y, et al. (2010) Pausing of RNA polymerase II disrupts DNA-specified nucleosome organization to enable precise gene regulation. Cell 143: 540-551.
36. Buratowski S (2003) The CTD code. Nat Struct Biol 10: 679-680.
37. Buratowski S (2009) Progression through the RNA polymerase II CTD cycle. Mol Cell 36: 541-546.
38. Biswas D, Milne TA, Basrur V, Kim J, Elenitoba-Johnson KS, et al. (2011) Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc Natl Acad Sci U S A 108: 15751-15756.
39. Luo Z, Lin C, Guest E, Garrett AS, Mohaghegh N, et al. (2012) The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output. Mol Cell Biol 32: 2608-2617.
40. Luo Z, Lin C, Shilatifard A (2012) The super elongation complex (SEC) family in transcriptional control. Nat Rev Mol Cell Biol 13: 543-547.
41. Takahashi H, Parmely TJ, Sato S, Tomomori-Sato C, Banks CA, et al. (2011) Human mediator subunit MED26 functions as a docking site for transcription elongation factors. Cell 146: 92-104.
42. Hu X, Malik S, Negroiu CC, Hubbard K, Velalar CN, et al. (2006) A Mediator-responsive form of metazoan RNA polymerase II. Proc Natl Acad Sci U S A 103: 9506-9511. (Pubitemid 43955855)
43. Wilda M, Busch K, Klose I, Keller T, Woessmann W, et al. (2004) Level of MYC overexpression in pediatric Burkitt's lymphoma is strongly dependent on genomic breakpoint location within the MYC locus. Genes Chromosomes Cancer 41: 178-182. (Pubitemid 39096744)
44. Kellner WA, Van Bortle K, Li L, Ramos E, Takenaka N, et al. (2013) Distinct isoforms of the Drosophila Brd4 homologue are present at enhancers, promoters and insulator sites. Nucleic Acids Res.
45. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, et al. (2013) Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153: 320-334.
46. Zhang W, Prakash C, Sum C, Gong Y, Li Y, et al. (2012) Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem 287: 43137-43155.
47. Peterlin BM, Brogie JE, Price DH (2012) 7SK snRNA: a noncoding RNA that plays a major role in regulating eukaryotic transcription. Wiley Interdiscip Rev RNA 3: 92-103.
48. Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM (2012) Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 287: 36609-36616.
49. Levens D (2010) You Don't Muck with MYC. Genes Cancer 1: 547-554.
50. Dooley S, Wundrack I, Welter C, Blin N (1994) Constitutive C-myc overexpression and p1/p2 promoter shift in a small-cell lung-cancer cell-line. Int J Oncol 5: 65-68. (Pubitemid 24179104)
51. Mohan M, Lin C, Guest E, Shilatifard A (2010) Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 10: 721-728.
52. Levine M (2011) Paused RNA polymerase II as a developmental checkpoint. Cell 145: 502-511.
53. Nechaev S, Fargo DC, dos Santos G, Liu L, Gao Y, et al. (2010) Global analysis of short RNAs reveals widespread promoter-proximal stalling and arrest of Pol II in Drosophila. Science 327: 335-338.